Late-Life Depression

LLD: Basics - Defining Despair

• Definition: Major Depressive Disorder (MDD) or clinically significant depressive symptoms with onset at age ≥60-65 years.
• Significance:
  • Common, yet often underdiagnosed & undertreated.
  • Impact: ↑ morbidity, ↑ mortality, ↓ Quality of Life (QoL).
• Epidemiology:
  • Prevalence:
    • Community: 1-5% (MDD), 10-15% (depressive symptoms).
    • Primary Care: 5-10%.
    • Long-term Care Facilities: 12-30%.
  • Gender: Higher prevalence in women (F > M).

⭐ Late-life depression is a significant risk factor for developing dementia.

LLD: Origins - Unraveling Roots

LLD's etiology is multifactorial, understood via a Biopsychosocial model:

• Biological Factors:
  • Neurotransmitter changes (↓ Serotonin, ↓ Norepinephrine, ↓ Dopamine)
  • HPA axis dysregulation (often ↑ cortisol)
  • Genetic predisposition (e.g., family history)
  • Cerebrovascular disease ('vascular depression' hypothesis)
    • Linked to white matter hyperintensities (WMHs)
  • Chronic inflammation (e.g., ↑ pro-inflammatory cytokines)
  • Structural brain changes (e.g., cortical atrophy, WMHs)
• Psychosocial Factors:
  • Chronic medical illness, disability, chronic pain
  • Polypharmacy (adverse effects, interactions)
  • Bereavement, social isolation, loneliness
  • Financial strain, caregiver burden
  • Past trauma or significant life stressors

⭐ The 'vascular depression' hypothesis posits that cerebrovascular lesions disrupt fronto-striatal-limbic pathways, increasing vulnerability to depression.

LLD: Presentation & Diagnosis - Spotting Shadows

• Core Symptoms (📌 SIGECAPS): DSM-5: ≥5 symptoms for ≥2 weeks (must include depressed mood or anhedonia).
  • Sleep disturbance
  • Interest ↓ (anhedonia)
  • Guilt/worthlessness
  • Energy ↓ (fatigue)
  • Concentration ↓
  • Appetite change/weight change
  • Psychomotor agitation/retardation
  • Suicidal ideation
• Atypical Presentations:
  • Prominent somatic complaints (pain, GI upset), anxiety, irritability, apathy.
  • Cognitive impairment ('depressive pseudodementia'), social withdrawal. Less overt sadness.
• Diagnosis:
  • DSM-5/ICD-11 criteria.
  • Screening: Geriatric Depression Scale (GDS-15 >5), PHQ-9 (>10).
• Differential Diagnosis:
  • Dementia (Alzheimer's, Vascular), Delirium.
  • Medical: Hypothyroidism, Parkinson's. Medication side effects.

⭐ In 'depressive pseudodementia', cognitive deficits often improve significantly with antidepressant treatment, unlike in true dementia where decline is progressive.

LLD: Management & Prognosis - Guiding Lights

General Principles:

• "Start low, go slow."
• Monitor side effects (e.g., hyponatremia with SSRIs, QTc prolongation, fall risk) & drug interactions.

Pharmacotherapy:

• First-line: SSRIs (e.g., Sertraline 25-50mg, Escitalopram 5-10mg).
• SNRIs (Venlafaxine, Duloxetine) as alternatives.
• Avoid TCAs, MAOIs if possible.
• Consider augmentation for partial response.

Psychotherapy:

• Problem-Solving Therapy (PST), Interpersonal Therapy (IPT), Cognitive Behavioral Therapy (CBT).
• Effective alone or combined with medication.

Electroconvulsive Therapy (ECT):

• For severe, treatment-resistant, psychotic depression, or urgent need (suicidality, inanition).

⭐ ECT is a safe, highly effective treatment for severe LLD, even in frail elderly, with precautions.

Other: Lifestyle modifications, social support.

Prognosis:

• Variable; ↑relapse, chronicity. Comorbidities impact. ⚠️ High suicide risk.

Treatment Algorithm:

High‑Yield Points - ⚡ Biggest Takeaways

• Late-life depression often presents with somatic symptoms, anxiety, not just overt sadness.
• Strong link to vascular risk factors, cerebrovascular disease (vascular depression).
• ↑ risk of cognitive impairment, dementia; consider pseudodementia.
• SSRIs first-line (start low, go slow); ECT safe, effective for severe/resistant cases.
• Higher suicide risk, particularly in older, isolated males.
• Often co-occurs with chronic medical illnesses, polypharmacy.
• Differentiate from normal bereavement, adjustment disorders.